NLSP

NLS Pharmaceutics AG (NLSP) ESG Analysis Analysis (2026)

Invetso Score: 5.6/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

NewcelX’s environmental risk profile is moderate, reflecting its limited operational footprint but also a lack of formal sustainability reporting. The company’s focus on innovative therapies could yield indirect environmental benefits if successful, but current disclosures and policies are minimal.

Social

Score:

NewcelX demonstrates social value through its focus on high-impact diseases and international partnerships. However, the absence of workforce and diversity disclosures limits transparency and comparability to best-in-class peers.

Governance

Score:

Governance practices at NewcelX are adequate for a clinical-stage biotech, with proper shareholder engagement on major transactions. However, the complex capital structure and limited board transparency present moderate governance risks.

Overall Score

Score:

NewcelX’s ESG profile is moderate, reflecting its early-stage status, limited operational footprint, and focus on high-impact diseases. The company’s strengths include addressing unmet medical needs and executing a cross-border merger with shareholder approval. However, gaps in environmental, workforce, and governance disclosures, as well as a complex capital structure, constrain its ESG standing relative to global peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on NLS Pharmaceutics AG. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →